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Abstract
Vancomycin-Intermediate Staphylococcus aureus (VISA) is still 
uncommon among MRSA isolates. In our region, we rarely encounter 
a case of VISA and/or GISA bacteremia. Here, we report a man who 
suffered from autoimmune hepatitis on immunosuppressive therapy 
and thoracic transverse myelitis suspected to be due to polyomavirus 
infection; he developed persistent MRSA blood stream infection, 
PVL-positive and MLST clonal complex 88 which is reported most 
commonly from Africa. A strain with Vancomycin susceptibility of 
4 – 6 µg/ml (VISA) was initially identified, retested again elsewhere 
and showed MIC of 2µg/ml and Teicoplanin susceptibility of 4µg/ml. 
Treatment failure occurred while attaining higher serum vancomycin 
levels than recommended and died. 
Keywords: Vancomycin-intermediate S. aureus, VISA, S. aureus, 
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Introduction
Soon after the initial cases of Vancomycin-Inter-
mediate Staphylococcus aureus (VISA) were report-
ed form Japan in1997, it relentlessly seems to be 
reported worldwide, predisposing for more vanco-
mycin resistant strains i.e. VRSA, though it is still a 
rare sporadic isolate. However, VISA strains, a more 
frequent isolates compromise glycopeptides activity 
and complicate the treatment regimens of patients 
infected with these strains [1].In an international 
study, hVISA phenotype (defined as the presence 
of subpopulations typically at a rate of 1 organism 
per 105–106 of MRSA with VISA) occurred in more 
than one-quarter of MRSA blood isolates from pa-
tients with infective endocarditis, though it varied 
in frequency by geographic region [2, 3].In Taiwan, 
isolates from ten centers collected 1000 MRSA, the 
prevalence of VISA isolates were 0.2% and hVISA 
isolates 0.7% [4].
In our region, reports from the Arab Countries 
have been published; In Jordan a case of VISA (MIC 
= 4 mg/dl) was reported in the year 2006 by F. 
Bakri and coworkers in a patient with erythroder-
mic psoriasis who suffered three months persistent 
Staphylococcus aureus bacteremia [5]. MRSA strains 
with decreased susceptibility for vancomycin were 
reported from Qassim region in Saudi Arabia [6]. 
VISA, hVISA persistent blood stream infection in 
spite of high blood vancomycin levels were report-
ed from Saudi Arabia as well [7]. Another interest-
ing report came from Oman on the treatment of 
infective endocarditis due to VISA; a patient was 
treated with a combination of intravenous linezolid 
and fusidic acid without a need for surgical inter-
vention and resulted in complete cure [8]. Moreover, 
a report on glycopeptide-intermediate Staphylococ-
cus aureus (GISA) were reported form north Leba-
non, five strains out of 113 (4.4%) were resistant 
to teicoplanin (GISA) by MIC dilution method and 
no strain was resistant to vancomycin. Although 
all MRSA isolates were reported as susceptible by 
Muller-Hinton agar diffusion method [9], we should 
consider other methods for testing MRSA for MIC 
when it is needed. 
Here, we present a patient who was immuno-
suppressed and had had suffered from persistent 
Staphylococcus aureus blood stream infection in 
spite of being on unintentional high serum levels of 
vancomycin. The isolate show discrepant susceptibil-
ity testing between different laboratories, once was 
interpreted as VISA, at another institution was not.
Case Report
A 47 year old male patient from Yemen with 
type 2 diabetes mellitus on insulin, and autoimmune 
hepatitis since 1996 on Immunosuppressive therapy; 
dexamethasone 4 mg/day and azathioprine 50 mg 
twice daily. He was admitted on November 1, 2014 
in Jordan hospital complaining of bilateral lower limb 
weakness of one month duration,it was sudden in 
onset and progressive, it was noticed when lifting 
heavy objects, and later falling down spontaneously 
on walking. Dorsal spine MRI imaging showed le-
sion in the anterior part of dorsal spine (Figure 1). 
Differential diagnosis included viral transverse myeli-
Figure 1. A lesion in the anterior part of the spinal cord 
opposing the lower part of T5 to the lower part of the T6 
vertebral bodies,it shows no significant enhancement in post 
contrast images.
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tis, demyelination, and low grade neoplasm.
He was transferred from another hospital with 
decrease level of consciousness; he was admit-
ted to the ICU, and on admission he was sleepy, 
generally week and could not move his legs. CSF 
analysis showed WBC = 44/mm3, RBC =100 /mm3, 
Protein=308 mg/dl, Glucose =148 mg/dl, he was 
started on ceftriaxone 2gm/12 hours and vancomy-
cin 1gm/12 hours. Dorsal MRI showed a lesion of 
the anterior part of the spinal cord ,extending op-
posite the lower part of D5 to the lower part of the 
D6 vertebral bodies, it show no significant enhance-
ment in the post contrast images (Figure 1). Dexa-
methasone was discontinued on November 3rd and 
methylprednisolone 1gm/24hours was started. On 
November 6th he started fever (38.60C orally) when 
an infectious diseases consultation was sought. Lab-
oratory tests for Clostridium difficile toxins, CMV 
IgM, toxoplasma IgM, urine legionella antigen, my-
coplasma IgM, and Chlamydophila pneumoniae 
IgM, HIV antibodies, HCV Antibodies and HBsAg 
were all negative. Urine sediment for decoy cells 
was positive, and BK-Polyomavius by Taq-Man real 
time PCR (Anatolia GeneworkInc, Istanbul, Turkey) 
was positive. Immunosuppressive therapy was ad-
vised to be tapered and ceftriaxone and vancomycin 
were discontinued as aerobic blood cultures twice 
showed no growth with abating fever. Few days 
later he redeveloped fever, and blood culture grew 
Enterobacter cloacae, he was started on pipracillin/
tazobactam 4.5 gm/8hours, fever subsided for sev-
eral days and the patient was relatively stable with 
his baseline neuro-deficit. A repeat dorsal spine MRI 
showed no significant changes from previous imag-
ing and no evidence of new lesions.
About a week later, the patient developed high 
fever (38.4 0C), and his blood cultures grew methi-
cillin-resistant Staphylococcus aureus (MRSA), van-
comycin 2gm IV loading followed by 1gm/12hours 
was started, 2D- echocardiogram was normal, and 
bone scan was reported as multiple abnormal areas 
of increased radiotracer uptake seen at both sterno-
clavicular joints, both knee joints, and irregular tracer 
uptake is seen at D5-D6 and D12 vertebral bodies. 
Five days into vancomycin treatment; on November 
19th fever persisted, and empiric fluconazole 600mg 
IV loading then 400mg IV/24hours was added, van-
comycin trough levels were monitored aiming to 
keep levels 15 - 20 µg/ml, althoughin most instances 
levels were unintentionally elevated due to meas-
ured deterioration in renal function (Figure 3). The 
patient did not have clinical response, vancomycin 
E-test (bioMérieux Marcy l’Etoile. 376, chemin de 
l’Orme 69280 Marcy l’Etoile) was done and initially 
showed complete resistance (CLSI MIC > 16 µg/ml), 
an immediate repeat of the E-test resulted in van-
comycin-intermediate Staphylococcus aureus (VISA) 
MIC = 4 – 6 µg/ml (CLSI MIC for VISA equals 4 – 8 
µg/ml) (Figure 2). Linezolid 600 mg IV/12hours and 
imipenem/cilastatin 250 mg/6 hours were started; 
the later and fluconazole were discontinued as re-
peat blood cultures showed the same S. aureus 
isolate. The patient showed continuous clinical de-
Figure 2. Muller-Hinton growth media with MRSA growth 
and E-test strip showing clear zone 4 – 6 µg/ml.
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terioration, white lungs on chest radiogram, poor 
arterial blood gases, electrolytes imbalance, further 
renal function deterioration, intractable shock and 
met his demise.
MIC and Molecular analysis
Due to E-testing discrepancy at our laboratory, a 
preserved Staphylococcus aureus isolate was retest-
ed for susceptibility by the (Antimicrobial Resistance 
and Healthcare-Associated Infections Reference 
Unit. Public Health England, 61 Colindale Avenue, 
London NW9 5EQ, Reference number PHE ref. No.: 
H1 5020 1048), and showed that vancomycin MIC 
was 2 µg/ml (CLSI vancomycin susceptible ≤ 2), 
while teicoplanin MIC was 4 µg/ml (CLSI suscepti-
ble ≤ 8). Staphylococcus aureus typing revealed spa 
type: t690, (repeat succession: 07-12-21-17-13-13-
34-34-34-33-34) and Panton-Valentine-Leukocidin 
(Luk-PV) positive strain.
Discussion
In our region, we rarely document patients with 
MRSA-induced sepsis with elevated or creeping 
MIC phenomena, and persistent bacteremia while 
on vancomycin treatment, due to resources limi-
tations. A case was presented by my group (Rula 
Rashed MD, Fadi Shaqlous PharmD) earlier in2010, 
in a regional meeting; the isolate demonstrated 
creeping vancomycin MIC [10] while the patient 
was on treatment with therapeutic vancomycin lev-
els, MIC creped in a month time from 0.125 µg/
ml, to 0.75 µg/ml, to 1.5 µg/ml as was verified by 
E-test. The patient continued to have pus discharge 
from a traumatized combat-related infected foot 
wound with repeated surgical debridement, till he 
was switched to linezolid with almost brisk response 
and discharged home (unpublished report).
Our current patient was immunocompromised, 
and had thoracic spinal cord transverse myelitis that 
was suspected to be due polyomavirus infection, 
which may have been predisposed by immunosup-
pressive therapy. Again he showed lack of response 
to vancomycin therapy, though the strain was with-
in the susceptibility range, and vancomycin serum 
levels were much higher than what was desired 
(Figure 3). Failure of vancomycin therapy for VISA 
strains is well described, as the target attainment 
(AUC/MIC ≥ 400) cannot be reached [11]. Higher 
failure rates were also reported with “creped” van-
comycin MIC, though still within susceptibility rang-
es of ≤ 2 µg/ml; the upper CLSI limit for vancomycin 
susceptibility [12, 13]. Our S. aureus isolate as re-
tested in (Antimicrobial Resistance and Healthcare-
Associated Infections Reference Unit. Public Health 
England, 61 Colindale Avenue, London NW9 5EQ), 
it exhibited vancomycin susceptibility and did not 
meet CLSI MIC level for GISA [12,14].The isolate 
belongs to spa type that has been associated with 
PVL-MRSA and belonging to MLST clonal complex 
88 reported most commonly from Africa. This mecA 
positive S. aureus encodes Pantone-Valentine leuco-
cidin (PVL) genes. Infection with PVL-SA most com-
monly presents as primary cutaneous lesions [15, 
16]. However PVL-positive S. aureus was reported to 
be associated with serious life threatening disease, 
namely community-associated pneumonia (CAP) in 
four patients, all did not have the classical risk fac-
tors for infection with strains carrying PVL genes 
[17].The patient was started on Linezolid but the 
duration of therapy was not enough to appreciate 
a response, and he died.
In our case, a lesson to be learned; laboratories 
should pay attention for microorganisms’ antimicro-
bial susceptibility testing, taking into account the 
imported tests kits source, storage and quality; here 
the E-tests strips that showed discrepant MIC val-
ues for .S aureus in the same laboratory and tests 
strips brand, though labeled as not expired; E-test 
(bioMérieux Marcy l’Etoile. 376, chemin de l’Orme 
69280 Marcy l’Etoile).
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Another lesson learned from this case, that a 
persistent fever in -compromised patients is a risk 
factor for the development of more antibiotic resist-
ant patterns of S. aureus infections and moreover 
in PVL-positive strains. This study also suggests the 
early implementation of antibiotic treatment based 
on suspicion of the frank pathogen, in order to 
cover strains with higher MICs, before the actual 
MIC is available [18].
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